Call for Papers

  • Home
  • Call for Papers

We accept abstract submission from
January 28, 2021 10:00 JST to May 31, 2021 18:00 JST.

ISA2021 invites your submission for papers to be presented at ISA2021 held in Hybrid Format (On-site in Kyoto, and online subscription) from October 24 – 27, 2021 (On-site, including live sessions) and until November 30, 2021 for on-demand subscription.

Please check the submission guidelines and follow the instructions.

Submission Guidelines

  • Abstracts can be submitted from 10:00 JST (JTS: GMT +9) on January 28, 2021 to 18:00 JST on May 31, 2021.
  • Abstracts must be submitted online only, through the designated submission site.
  • Abstracts must be written in English.
  • Abstracts are to be submitted for poster presentation*. Some distinguished papers will be selected to present at oral sessions.
  • Number of abstract submissions as the main author is limited to 2 (two) per author. However, this does not limit the submission as co-authors of the abstracts.
  • All submissions will be peer reviewed. The Organizing Committee has the right to make the final decision on all submissions.
  • Abstracts that are accepted must be presented by the pre-registered author.
  • The abstracts will be published in the abstract App. exactly as submitted.
  • The body of the abstract should not exceed 350 words in English.
  • The title of the abstract should not exceed 40 words in English.
  • Up to 2 supporting files (i.e. images, graphs, tables) can accompany the abstract body.
  • Accepted submitters are required to complete their registration and payment within 2 weeks of notification of acceptance. Those who failed to register by the designated date will not be included in the program.
  • * Poster presentations will also be organised in a hybrid format. Detailed instruction will be announced in due course.

The program will be arranged according to the following tracks. You can select up to 3 topics/keywords which fit your paper the most.


Dyslipidemia Lipids, lipoproteins and apolipoproteins
Pathogenesis Endothelium, macrophages, smooth muscle cells, thrombosis, inflammation, immunity, microbiome
Epidemiology Risk factors, add obesity and diabetes, population health, vulnerable communities, children and adolescents
Prevention Lifestyle measures and pharmacological intervention
Therapeutics Pharmacologic intervention, new treatment modalities, late breaking clinical trials


  • Basic science
  • Clinical aspects of CVD
  • Clinical studies
  • COVID-19
  • Diabetes and new therapies
  • Endothelium
  • Epidemiology of CVD and risk stratification
  • Evidence-based lifestyle intervention
  • Familial hypercholesterolemia and LDL
  • Genetics
  • Guidelines updates
  • HDL function
  • Imaging and atherosclerosis
  • Imaging of CVD
  • Inflammation and the immune system
  • Late-breaking clinical trials
  • Lipoprotein metabolism
  • Macrophages
  • Metabolic Syndrome
  • NASH
  • Nutrition and lifestyle
  • Pathogenesis of atherosclerosis
  • PCSK9
  • Pharmacology of CVD
  • Reverse cholesterol transport
  • Thrombosis
  • Triglyceride-rich lipoproteins and non-HDL
  • Others

Submission Procedure

  1. Access the Submission Page, and create your account first.
  2. Enter necessary information and abstract body by following the instruction given on the submission page, and submit.
  3. Modifications and updates or your submitted paper is possible until May 31, 2021 18:00 JST by using your user ID and password.
  4. After May 31, 2021 18:00 JST no changes or updates are accepted.